Sana Biotechnology (SANA) Rated 'Market Perform' on Diabetes Program Prospects

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the penny stocks that will skyrocket. On June 24, analysts at Citizens JMP reiterated a ‘Market Outperform’ rating on the stock and a $5 price target. The positive stance follows the updating of clinical data from a diabetes program.

Clinical trial results presented at the American Diabetes Association conference from the UP421 cadaveric pancreatic islet cell program demonstrated that the treatment was safe and well-tolerated in patients with Type 1 diabetes.

According to Citizens JMP, six-month follow-up data from a modified pancreatic islet cell program should validate Sana’s HIP platform in Type 1 diabetes. The research firm is also optimistic about Sana Biotechnology’s SC291 program for autoimmune disease, which is expected to be available in 2025.

Sana Biotechnology, Inc. (NASDAQ:SANA) develops engineered cells as medicines for patients. It aims to repair and control genes, replace missing or damaged cells, and make therapies broadly accessible.

While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 9 Best AI Stocks to Buy According to Billionaire Stanley Druckenmiller and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty.

Disclosure: None. This article is originally published at Insider Monkey.